Decreased risk of acute gastrointestinal toxicity when substituting methotrexate with mycophenolate mofetil in the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning regimens [4]

Bone Marrow Transplantation

Volumn 37, Issue 2, 2006, Pages 235-236

  Pohlreich, David ^a   Vitek, A ^a   Maalouf, J ^a   Cetkovsky, P ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

DRUG RESPONSE; DRUG SUBSTITUTION; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MUCOSITIS; MYCOPHENOLIC ACID; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 30944452208     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705227     Document Type: Letter

References (6)

1. Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U et al. Cyclosporine A and mycofenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical sibling. Bone Marrow Transplant 2005; 35: 1089-1093.
2. Niederwieser D, Maris M, Schizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total irradiation (TBI) and fludarabin followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycofenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological disease. Blood 2003; 101: 1620-1629.
3. Bornhauser M, Schuler U, Porksen G, Naumann R, Geissler G, Thiede C et al. Mycofenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999; 67: 499-509.
4. Pohlreich D, Vitek A, Valkova V, Markova M, Maalouf J, Kouba M et al. Cyclosporine-methotrexate versus cyclosporine-mycophenolate in the prevention of GvHD in stem cell transplantation using, myeloablative regimens. Bone Marrow Transplant 2005; 35 (Suppl 2): 149.
5. Bolwell BJ, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporin+short course methotrexate to cyclosporine+ mycophenolate for GVHD prophylaxis in ablative allogeneic BMT. Bone Marrow Transplant 2004; 34: 621-625.
6. Kiehl MG, Schafer-Eckart K, Kroger M, Bornhauser M, Basara N, Blau IW et al. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host-disease in stem cell transplant recipients. Transplant Proc 2002; 34: 2922-2924.